These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 26328949)

  • 41. Validating ADME QSAR Models Using Marketed Drugs.
    Siramshetty V; Williams J; Nguyễn ÐT; Neyra J; Southall N; Mathé E; Xu X; Shah P
    SLAS Discov; 2021 Dec; 26(10):1326-1336. PubMed ID: 34176369
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In silico approaches for predicting ADME properties of drugs.
    Yamashita F; Hashida M
    Drug Metab Pharmacokinet; 2004 Oct; 19(5):327-38. PubMed ID: 15548844
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In silico pharmacology for a multidisciplinary drug discovery process.
    Ortega SS; Cara LC; Salvador MK
    Drug Metabol Drug Interact; 2012; 27(4):199-207. PubMed ID: 23152402
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Advances in computationally modeling human oral bioavailability.
    Wang J; Hou T
    Adv Drug Deliv Rev; 2015 Jun; 86():11-6. PubMed ID: 25582307
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Improving compound quality through in vitro and in silico physicochemical profiling.
    van de Waterbeemd H
    Chem Biodivers; 2009 Nov; 6(11):1760-6. PubMed ID: 19937820
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling.
    Ekins S; Mestres J; Testa B
    Br J Pharmacol; 2007 Sep; 152(1):9-20. PubMed ID: 17549047
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Selecting oral bioavailability enhancing formulations during drug discovery and development.
    Leucuta SE
    Expert Opin Drug Discov; 2014 Feb; 9(2):139-50. PubMed ID: 24387781
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Recent advances in physicochemical and ADMET profiling in drug discovery.
    Wang J; Skolnik S
    Chem Biodivers; 2009 Nov; 6(11):1887-99. PubMed ID: 19937823
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Artificial intelligence in drug design.
    Zhong F; Xing J; Li X; Liu X; Fu Z; Xiong Z; Lu D; Wu X; Zhao J; Tan X; Li F; Luo X; Li Z; Chen K; Zheng M; Jiang H
    Sci China Life Sci; 2018 Oct; 61(10):1191-1204. PubMed ID: 30054833
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Characterisation of data resources for in silico modelling: benchmark datasets for ADME properties.
    Przybylak KR; Madden JC; Covey-Crump E; Gibson L; Barber C; Patel M; Cronin MTD
    Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):169-181. PubMed ID: 28375027
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Quantitative structure/activity relationship modelling of pharmacokinetic properties using genetic algorithm-combined partial least squares method.
    Yamashita F; Fujiwara S; Wanchana S; Hashida M
    J Drug Target; 2006; 14(7):496-504. PubMed ID: 17062396
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Importance of molecular computer modeling in anticancer drug development.
    Geromichalos GD
    J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Application of in silico approaches to predicting drug--drug interactions.
    Ekins S; Wrighton SA
    J Pharmacol Toxicol Methods; 2001; 45(1):65-9. PubMed ID: 11489666
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The survey of the use of QSAR methods to determine intestinal absorption and oral bioavailability during drug design.
    Silva FT; Trossini GH
    Med Chem; 2014; 10(5):441-8. PubMed ID: 24730584
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ligand-based design, in silico ADME-Tox filtering, synthesis and biological evaluation to discover new soluble 1,4-DHP-based CFTR activators.
    Visentin S; Ermondi G; Medana C; Pedemonte N; Galietta L; Caron G
    Eur J Med Chem; 2012 Sep; 55():188-94. PubMed ID: 22889557
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Predicting ADME properties and side effects: the BioPrint approach.
    Krejsa CM; Horvath D; Rogalski SL; Penzotti JE; Mao B; Barbosa F; Migeon JC
    Curr Opin Drug Discov Devel; 2003 Jul; 6(4):470-80. PubMed ID: 12951810
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Considerations and recent advances in QSAR models for cytochrome P450-mediated drug metabolism prediction.
    Li H; Sun J; Fan X; Sui X; Zhang L; Wang Y; He Z
    J Comput Aided Mol Des; 2008 Nov; 22(11):843-55. PubMed ID: 18574695
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Using in vitro human tissues to predict pharmacokinetic properties.
    Huebert ND; Dasgupta M; Chen Y
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):69-74. PubMed ID: 14982150
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In Silico and Ex silico ADME approaches for drug discovery.
    Darvas F; Keseru G; Papp A; Dormán G; Urge L; Krajcsi P
    Curr Top Med Chem; 2002 Dec; 2(12):1287-304. PubMed ID: 12470281
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In silico prediction of the solubility advantage for amorphous drugs - Are there property-based rules for drug discovery and early pharmaceutical development?
    Kuentz M; Imanidis G
    Eur J Pharm Sci; 2013 Feb; 48(3):554-62. PubMed ID: 23262058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.